Genelux Corp [GNLX] stock is trading at $5.59, up 5.67%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GNLX shares have gain 11.80% over the last week, with a monthly amount drifted -26.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genelux Corp [NASDAQ: GNLX] stock has seen the most recent analyst activity on October 21, 2025, when Lake Street initiated its Buy rating and assigned the stock a price target of $16. Previously, Guggenheim started tracking the stock with Buy rating on October 29, 2024, and set its price target to $8. On August 28, 2024, ROTH MKM initiated with a Buy rating and assigned a price target of $10 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $35 on November 27, 2023. Maxim Group initiated its recommendation with a Buy and recommended $40 as its price target on September 12, 2023. The Benchmark Company started tracking with a Speculative Buy rating for this stock on February 15, 2023, and assigned it a price target of $10.
Genelux Corp [GNLX] stock has fluctuated between $1.99 and $8.53 over the past year. Currently, Wall Street analysts expect the stock to reach $17.33 within the next 12 months. Genelux Corp [NASDAQ: GNLX] shares were valued at $5.59 at the most recent close of the market. An investor can expect a potential return of 210.02% based on the average GNLX price forecast.
Analyzing the GNLX fundamentals
Gross Profit Margin for this corporation currently stands at -0.57% with Operating Profit Margin at -37.44%, Pretax Profit Margin comes in at -35.57%, and Net Profit Margin reading is -35.57%. To continue investigating profitability, this company’s Return on Assets is posted at -1.28, Equity is -1.29 and Total Capital is -1.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.29 points at the first support level, and at 4.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.81, and for the 2nd resistance point, it is at 6.03.
Ratios To Look Out For
For context, Genelux Corp’s Current Ratio is 4.20. In addition, the Quick Ratio stands at 4.20 and the Cash Ratio stands at 0.92.
Transactions by insiders
Recent insider trading involved Ryder Sean, General Counsel, that happened on May 12 ’25 when 4475.0 shares were sold. President and CEO, Zindrick Thomas completed a deal on May 12 ’25 to sell 10764.0 shares. Meanwhile, VP, Clinical Trial Operations Yu Yong sold 5579.0 shares on May 12 ’25.
